Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-547 for super-refractory status epilepticus
NL-OMON43720Phase 3Active, not recruiting
- Sponsor
- Sage Therapeutics
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brexanolone in status epilepticus (SE) and epilepsy (3 arms), sponsored by Sage Therapeutics. Primary endpoint: Primary response. Started Aug 2016; status: active, not recruiting.
02
Drugs
brexanolone
03
Conditions
status epilepticus (SE)epilepsy
Beyond the preview
Go deeper on NL-OMON43720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43720.